AR076164A1 - Inhibidores de anillos fusionados de hepatitis c - Google Patents
Inhibidores de anillos fusionados de hepatitis cInfo
- Publication number
- AR076164A1 AR076164A1 ARP100101000A ARP100101000A AR076164A1 AR 076164 A1 AR076164 A1 AR 076164A1 AR P100101000 A ARP100101000 A AR P100101000A AR P100101000 A ARP100101000 A AR P100101000A AR 076164 A1 AR076164 A1 AR 076164A1
- Authority
- AR
- Argentina
- Prior art keywords
- heterocycle
- heteroaryl
- group
- cycloalkyl
- aryl
- Prior art date
Links
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 18
- 125000003118 aryl group Chemical group 0.000 abstract 14
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 14
- 125000001072 heteroaryl group Chemical group 0.000 abstract 14
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 13
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 13
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 7
- 125000001589 carboacyl group Chemical group 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 229940124530 sulfonamide Drugs 0.000 abstract 7
- 150000003456 sulfonamides Chemical class 0.000 abstract 7
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 abstract 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical group 0.000 abstract 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- -1 -OH Chemical group 0.000 abstract 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000006168 tricyclic group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16434209P | 2009-03-27 | 2009-03-27 | |
| US21488309P | 2009-04-28 | 2009-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076164A1 true AR076164A1 (es) | 2011-05-26 |
Family
ID=42781523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101000A AR076164A1 (es) | 2009-03-27 | 2010-03-29 | Inhibidores de anillos fusionados de hepatitis c |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9150554B2 (enExample) |
| EP (1) | EP2410843A4 (enExample) |
| JP (1) | JP5735482B2 (enExample) |
| KR (1) | KR20110131312A (enExample) |
| CN (1) | CN102427726B (enExample) |
| AR (1) | AR076164A1 (enExample) |
| AU (1) | AU2010229795A1 (enExample) |
| BR (1) | BRPI1012282A2 (enExample) |
| CA (1) | CA2755658A1 (enExample) |
| CL (1) | CL2011002377A1 (enExample) |
| CO (1) | CO6450600A2 (enExample) |
| EA (1) | EA201190224A1 (enExample) |
| IL (1) | IL215202A0 (enExample) |
| MX (1) | MX2011010132A (enExample) |
| PE (1) | PE20120773A1 (enExample) |
| SG (1) | SG174883A1 (enExample) |
| TW (1) | TW201038560A (enExample) |
| WO (1) | WO2010111534A1 (enExample) |
| ZA (1) | ZA201107753B (enExample) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011006333A (es) | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
| CN102264737A (zh) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | 抗病毒化合物 |
| US8314135B2 (en) | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
| US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8242156B2 (en) | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8507522B2 (en) | 2009-03-06 | 2013-08-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| PE20120773A1 (es) | 2009-03-27 | 2012-07-19 | Presidio Pharmaceuticals Inc | Anillos triciclicos fusionados sustituidos como inhibidores del virus de hepatitis c |
| US20190127365A1 (en) | 2017-11-01 | 2019-05-02 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus replication |
| NZ595410A (en) | 2009-03-27 | 2013-12-20 | Merck Sharp & Dohme | Inhibitors of hepatitis c virus replication |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| RU2541571C2 (ru) | 2009-04-15 | 2015-02-20 | Эббви Инк. | Противовирусные соединения |
| AU2010249080A1 (en) * | 2009-05-12 | 2012-01-12 | Merck Sharp & Dohme Corp. | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| KR20180028070A (ko) | 2009-05-13 | 2018-03-15 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| UA118080C2 (uk) | 2009-06-11 | 2018-11-26 | Еббві Айрленд Анлімітед Компані | Противірусні сполуки |
| US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| JP2012533569A (ja) | 2009-07-16 | 2012-12-27 | ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド | フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体 |
| ME02847B (me) | 2009-07-27 | 2018-01-20 | Gilead Sciences Inc | Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala |
| EP2473056A4 (en) | 2009-09-04 | 2013-02-13 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS |
| US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8703938B2 (en) | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8759332B2 (en) | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011031904A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
| US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8927709B2 (en) | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN104530079B (zh) * | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EA201201031A1 (ru) | 2010-01-25 | 2013-02-28 | Энанта Фармасьютиклз, Инк. | Ингибиторы вируса гепатита с |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| US8178531B2 (en) | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| KR20120124495A (ko) | 2010-03-04 | 2012-11-13 | 이난타 파마슈티칼스, 인코포레이티드 | Ｈｃｖ 복제의 억제제로서의 조합 제약 작용제 |
| CN102869657A (zh) | 2010-03-24 | 2013-01-09 | 沃泰克斯药物股份有限公司 | 用于治疗或预防黄病毒感染的类似物 |
| EP2555622A4 (en) | 2010-04-09 | 2013-09-18 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
| WO2012003642A1 (en) * | 2010-07-09 | 2012-01-12 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and use thereof for treating viral diseases |
| WO2012018534A2 (en) * | 2010-07-26 | 2012-02-09 | Schering Corporation | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| EP2603080A4 (en) | 2010-08-12 | 2014-01-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| CA2812779A1 (en) | 2010-09-29 | 2012-04-19 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
| AU2011328980B2 (en) | 2010-11-17 | 2015-07-30 | Gilead Sciences, Inc. | Antiviral compounds |
| RU2452735C1 (ru) | 2010-11-30 | 2012-06-10 | Александр Васильевич Иващенко | Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012122716A1 (en) * | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
| ES2648820T3 (es) | 2011-05-10 | 2018-01-08 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de los canales de sodio |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| JP5669984B2 (ja) | 2011-05-18 | 2015-02-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | ５−アザスピロ［２．４］ヘプタン−６−カルボン酸およびその誘導体の製造方法 |
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| CA2841095A1 (en) | 2011-07-09 | 2013-01-17 | Sunshine Lake Pharma Co., Ltd. | Spiro compounds as hepatitis c virus inhibitors |
| US8889726B2 (en) | 2011-08-08 | 2014-11-18 | Glaxosmithkline Llc | Chemica compounds |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| AU2012308295B2 (en) | 2011-09-16 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating HCV |
| DK2907816T3 (en) | 2011-11-16 | 2018-09-24 | Gilead Pharmasset Llc | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| NZ628515A (en) | 2012-02-10 | 2016-06-24 | Lupin Ltd | Antiviral compounds with a dibenzooxaheterocycle moiety |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| CN103420991B (zh) * | 2012-05-17 | 2017-07-07 | 乳源东阳光药业有限公司 | 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用 |
| TWI610916B (zh) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
| WO2014082379A1 (en) | 2012-11-29 | 2014-06-05 | Sunshine Lake Pharma Co.,Ltd. | Spiro ring compound as hepatitis c virus (hcv) inhibitor and uses thereof field of the invention |
| WO2014082380A1 (en) * | 2012-11-29 | 2014-06-05 | Sunshine Lake Pharma Co., Ltd. | Fused ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof |
| WO2014110687A1 (en) | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases |
| MY172166A (en) | 2013-01-31 | 2019-11-15 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| RU2507201C1 (ru) | 2013-02-07 | 2014-02-20 | Александр Васильевич Иващенко | Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2015009744A1 (en) | 2013-07-17 | 2015-01-22 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of hcv |
| EP3650014B1 (en) | 2013-08-27 | 2021-10-06 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| WO2015110048A1 (en) | 2014-01-23 | 2015-07-30 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PE20181884A1 (es) | 2016-04-07 | 2018-12-07 | Glaxosmithkline Ip Dev Ltd | Amidas heterociclicas utiles como moduladores de proteinas |
| WO2017181383A1 (en) * | 2016-04-21 | 2017-10-26 | Merck Sharp & Dohme Corp. | Hepatitis c virus inhibitors |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| BR112020026746A2 (pt) | 2018-07-13 | 2021-03-30 | Gilead Sciences, Inc. | Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição. |
| CN112955435B (zh) | 2018-10-24 | 2024-09-06 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| US12037340B2 (en) | 2021-05-21 | 2024-07-16 | Gilead Sciences, Inc. | Pentacyclic derivatives as Zika virus inhibitors |
| CN117321059A (zh) | 2021-05-21 | 2023-12-29 | 吉利德科学公司 | 用于治疗寨卡病毒感染的四环化合物 |
| JP7728367B2 (ja) | 2021-06-14 | 2025-08-22 | スコーピオン・セラピューティクス・インコーポレイテッド | がんを処置するために使用され得る尿素誘導体 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL127610C (enExample) * | 1965-06-23 | |||
| CH532608A (de) * | 1969-12-17 | 1973-01-15 | Ciba Geigy Ag | Verfahren zur Herstellung von Bis-aroxazolyl-Verbindungen |
| CH553807A (de) * | 1970-12-23 | 1974-09-13 | Sandoz Ag | Verfahren zur herstellung von dibenzthiophendioxidderivaten. |
| US3808206A (en) | 1971-06-29 | 1974-04-30 | Richardson Merrell Inc | Bis-basic ketones of phenoxathiins and antiviral compositions thereof |
| US4371690A (en) * | 1979-07-12 | 1983-02-01 | E. I. Du Pont De Nemours And Company | Heat-resistant rigid polymers from difunctional 9,10-dihydro-9,10-ethanoanthracenes |
| US5288914A (en) * | 1984-08-27 | 1994-02-22 | The Dow Chemical Company | Poly(arylcyclobutenes) |
| US5288924A (en) * | 1992-09-18 | 1994-02-22 | Mobil Oil Corporation | Process for starting up an olefin hydration reactor |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| TR199802136T2 (xx) | 1996-04-23 | 2001-06-21 | Vertex Pharmaceuticals Incorporated | �MPDH enzimi inhibit�rleri olarak �re t�revleri. |
| CZ298749B6 (cs) | 1996-10-18 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| ATE244717T1 (de) | 1997-03-14 | 2003-07-15 | Vertex Pharma | Inhibitoren des impdh-enzyms |
| US6010848A (en) | 1997-07-02 | 2000-01-04 | Smithkline Beecham Corporation | Screening methods using an atpase protein from hepatitis C virus |
| WO1999007734A2 (en) | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
| ATE298317T1 (de) | 1998-07-27 | 2005-07-15 | Angeletti P Ist Richerche Bio | Diketosäure-derivate als hemmstoffe von polymerasen |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| JP2002523371A (ja) | 1998-08-21 | 2002-07-30 | バイロファーマ・インコーポレイテッド | ウイルス感染および関連疾患を治療または予防するための化合物、組成物および方法 |
| CA2343522A1 (en) | 1998-09-04 | 2000-03-16 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
| EP1115286A4 (en) | 1998-09-25 | 2003-07-23 | Viropharma Inc | METHOD FOR TREATING AND PREVENTING VIRAL INFECTIONS AND DISEASES RELATED TO THEM |
| ES2405316T3 (es) | 1999-03-19 | 2013-05-30 | Vertex Pharmaceuticals Incorporated | Inhibidores de la enzima IMPDH |
| US6242602B1 (en) * | 1999-03-29 | 2001-06-05 | Gentex Corporation | One pot synthesis of 5,10-dihydrophenazine compounds and 5,10-substituted dihydrophenazines |
| US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
| US20040034041A1 (en) | 2000-05-10 | 2004-02-19 | Dashyant Dhanak | Novel anti-infectives |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| EP1256628A3 (en) | 2001-05-10 | 2003-03-19 | Agouron Pharmaceuticals, Inc. | Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof |
| US6887877B2 (en) | 2001-06-11 | 2005-05-03 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of Flavivirus infections |
| CN101624391A (zh) | 2001-06-11 | 2010-01-13 | 病毒化学医药公司 | 用作黄病毒感染抗病毒剂的噻吩衍生物 |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| JP2003212846A (ja) * | 2001-06-26 | 2003-07-30 | Japan Tobacco Inc | 縮合環化合物及びｃ型肝炎治療剤 |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| UA85366C2 (en) * | 2001-07-25 | 2009-01-26 | Бёрингер Ингельхайм (Канада) Лтд. | Viral polymerase inhibitors |
| ES2289161T3 (es) | 2001-11-02 | 2008-02-01 | Glaxo Group Limited | Derivados de 4-(heteroaril de 6 miembros)-acil pirrolidina como inhibidores de hcv. |
| US20050009873A1 (en) | 2001-11-02 | 2005-01-13 | Gianpaolo Bravi | Acyl dihydro pyrrole derivatives as hcv inhibitors |
| US20050043545A1 (en) | 2001-11-02 | 2005-02-24 | Gianpalol Bravi | 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors |
| BRPI0506948B1 (pt) | 2004-01-30 | 2018-09-18 | Medivir Ab | inibidores de serina protease ns-3 de hcv |
| EP1804786A4 (en) * | 2004-09-29 | 2008-01-02 | Cytovia Inc | SUBSTITUTED N-ARYL-9-OXO-9H-FLUORENE-1-CARBOXAMIDES AND ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS |
| WO2006050496A1 (en) * | 2004-11-02 | 2006-05-11 | E.I. Dupont De Nemours And Company | Substituted anthracenes and electronic devices containing the substituted anthracenes |
| DE102005022020A1 (de) * | 2005-05-12 | 2006-11-23 | Merckle Gmbh | Dibenzocycloheptanverbindungen und pharmazeutische Mittel, welche diese Verbindungen enthalten |
| US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US7759495B2 (en) * | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7745636B2 (en) | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741347B2 (en) * | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7728027B2 (en) * | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| US8629171B2 (en) * | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5266786B2 (ja) * | 2008-02-20 | 2013-08-21 | 富士ゼロックス株式会社 | 新規なフェノチアジン化合物 |
| WO2010096462A1 (en) * | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
| PE20120773A1 (es) | 2009-03-27 | 2012-07-19 | Presidio Pharmaceuticals Inc | Anillos triciclicos fusionados sustituidos como inhibidores del virus de hepatitis c |
-
2010
- 2010-03-25 PE PE2011001719A patent/PE20120773A1/es not_active Application Discontinuation
- 2010-03-25 CN CN201080021446.2A patent/CN102427726B/zh not_active Expired - Fee Related
- 2010-03-25 MX MX2011010132A patent/MX2011010132A/es active IP Right Grant
- 2010-03-25 SG SG2011067683A patent/SG174883A1/en unknown
- 2010-03-25 WO PCT/US2010/028730 patent/WO2010111534A1/en not_active Ceased
- 2010-03-25 CA CA2755658A patent/CA2755658A1/en not_active Abandoned
- 2010-03-25 EP EP10756872A patent/EP2410843A4/en not_active Withdrawn
- 2010-03-25 BR BRPI1012282A patent/BRPI1012282A2/pt not_active IP Right Cessation
- 2010-03-25 US US13/260,378 patent/US9150554B2/en not_active Expired - Fee Related
- 2010-03-25 KR KR1020117025221A patent/KR20110131312A/ko not_active Withdrawn
- 2010-03-25 AU AU2010229795A patent/AU2010229795A1/en not_active Abandoned
- 2010-03-25 JP JP2012502264A patent/JP5735482B2/ja not_active Expired - Fee Related
- 2010-03-25 EA EA201190224A patent/EA201190224A1/ru unknown
- 2010-03-26 TW TW099109325A patent/TW201038560A/zh unknown
- 2010-03-29 AR ARP100101000A patent/AR076164A1/es unknown
-
2011
- 2011-09-18 IL IL215202A patent/IL215202A0/en unknown
- 2011-09-26 CL CL2011002377A patent/CL2011002377A1/es unknown
- 2011-10-24 ZA ZA2011/07753A patent/ZA201107753B/en unknown
- 2011-10-27 CO CO11145231A patent/CO6450600A2/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US9150554B2 (en) | 2015-10-06 |
| EA201190224A1 (ru) | 2012-03-30 |
| CN102427726A (zh) | 2012-04-25 |
| WO2010111534A1 (en) | 2010-09-30 |
| CN102427726B (zh) | 2014-10-08 |
| PE20120773A1 (es) | 2012-07-19 |
| EP2410843A4 (en) | 2012-08-08 |
| BRPI1012282A2 (pt) | 2015-09-22 |
| TW201038560A (en) | 2010-11-01 |
| EP2410843A1 (en) | 2012-02-01 |
| HK1166446A1 (en) | 2012-11-02 |
| CO6450600A2 (es) | 2012-05-31 |
| CL2011002377A1 (es) | 2012-01-20 |
| SG174883A1 (en) | 2011-11-28 |
| AU2010229795A1 (en) | 2011-10-13 |
| IL215202A0 (en) | 2011-12-29 |
| US20120040962A1 (en) | 2012-02-16 |
| MX2011010132A (es) | 2011-10-14 |
| JP2012522003A (ja) | 2012-09-20 |
| JP5735482B2 (ja) | 2015-06-17 |
| KR20110131312A (ko) | 2011-12-06 |
| ZA201107753B (en) | 2012-07-25 |
| CA2755658A1 (en) | 2010-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076164A1 (es) | Inhibidores de anillos fusionados de hepatitis c | |
| AR084720A1 (es) | Inhibidores de anillos fusionados triciclicos de hepatitis c | |
| AR080264A1 (es) | Inhibidores ns5a de vhc | |
| AR080263A1 (es) | Inhibidores ns5a de vhc | |
| AR084388A1 (es) | Compuestos nitrogenados heterociclicos inhibidores de la replicacion del vhc y composiciones farmaceuticas que los contienen | |
| AR081848A1 (es) | Inhibidores de la proteina ns5a del vhc | |
| AR058776A1 (es) | Compuesto de piridina condensado | |
| ES2515194T3 (es) | Derivados de pirrolidina | |
| AR091790A1 (es) | Derivados de isoquinolin-1-ona y sus usos | |
| AR082885A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
| AR073315A1 (es) | Compuestos heterociclicos antivirales | |
| ES2655391T3 (es) | Inhibidores isoindolinona de fosfatidilinositol 3-quinasa | |
| AR063311A1 (es) | Compuestos organicos | |
| AR084280A1 (es) | Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos | |
| AR063601A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| AR082029A1 (es) | Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt | |
| AR060173A1 (es) | Derivados de piridina y de pirimidina como antagonistas del mglur2, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos del snc. | |
| CO5011121A1 (es) | Derivados de isotiazol utiles como agentes anticancerosos | |
| AR049443A1 (es) | Derivados de pirrolpiridinas | |
| AR076170A1 (es) | Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden. | |
| AR058700A1 (es) | Compuestos heterociclicos como bloqueadores del canal de sodio epitelial | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| AR077598A1 (es) | Compuestos heterociclicos fusionados como modulares de canales ionicos | |
| AR061629A1 (es) | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas | |
| ES2570756T3 (es) | Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |